Clinical Trial: Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: A Multicenter Study to Evaluate the Anti-viral Activity of an Interferonfree Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4)and Sofosbuvir+Ribavirin(G2)for Pts With Hepatitis C

Brief Summary: This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir ± ribavirin (genotype 1, 3 and 4) or sofosbuvir + ribavirin (genotype 2) for patients with hepatitis C virus-associated indolent B-cell lymphomas (HCV-RNA positive).